Purple Biotech (PPBT) Change in Accured Expenses (2018 - 2026)
Purple Biotech (PPBT) reported Change in Accured Expenses of $296000.0 for Q1 2026, up 127.69% year-over-year from $130000.0 in Q1 2025, and down 2.95% quarter-over-quarter from $305000.0 in Q4 2025.
Purple Biotech (PPBT) Change in Accured Expenses (2018 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 9 years of Change in Accured Expenses data on file, last reported at $296000.0 in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at $296000.0, up 127.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $371000.0 (up 123.92% YoY), and the FY2025 annual result was $205000.0, up 108.72% from the prior year.
- Change in Accured Expenses retreated to $296000.0 in Q1 2026 per PPBT's latest filing, from $305000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $2.7 million in Q1 2022 and troughed at -$1.5 million in Q1 2023.
- A 5-year average of -$46764.7 and a median of -$2000.0 in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses plunged 2106.06% in 2024, then jumped 145.25% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at $1.6 million in 2022, then slumped by 89.07% to $179000.0 in 2023, then sank by 476.54% to -$674000.0 in 2024, then jumped by 145.25% to $305000.0 in 2025, then slipped by 2.95% to $296000.0 in 2026.
- Business Quant data shows PPBT's Change in Accured Expenses at $296000.0 in Q1 2026, $305000.0 in Q4 2025, and -$2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Purple Biotech | 242.86 Mn | 236.43 Mn | - | 296,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 296,000.00 |
| Mar 31, 2026 | 296,000.00 |
| Dec 31, 2025 | 305,000.00 |
| Dec 31, 2025 | 305,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -228,000.00 |
| Jun 30, 2025 | -228,000.00 |
| Mar 31, 2025 | 130,000.00 |
| Mar 31, 2025 | 130,000.00 |
| Dec 31, 2024 | -674,000.00 |
| Dec 31, 2024 | -674,000.00 |
| Sep 30, 2024 | -345,000.00 |
| Sep 30, 2024 | -345,000.00 |
| Jun 30, 2024 | -662,000.00 |
| Jun 30, 2024 | -662,000.00 |
| Mar 31, 2024 | -671,000.00 |
| Mar 31, 2024 | -671,000.00 |
| Dec 31, 2023 | 179,000.00 |
| Dec 31, 2023 | 179,000.00 |